KM Research Hub
← 返回论文库
已完成 入排:排除 图源:可得 入排置信度 0.96

Health-related quality of life analysis of the LEAP-002 study of lenvatinib plus pembrolizumab versus lenvatinib as first-line treatment for advanced hepatocellular carcinoma.

R S Finn, M Kudo, P Merle, T Meyer, S Qin, M Ikeda, R Xu, J Edeline, B-Y Ryoo, Z Ren, A-L Cheng, P R Galle, S Kaneko, H Kumada, S Kamble, J M Norquist, K Mody, A Wang, L Dubrovsky, J M Llovet

ESMO Open 10(6) 105065

PMID40435872
PMCIDPMC12158521
DOI10.1016/j.esmoop.2025.105065
发表日期2025-05-28
入排依据:属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
摘要

摘要

BACKGROUND: Patients with advanced hepatocellular carcinoma (HCC) have a substantial symptom burden that affects their health-related quality of life (HRQoL). Assessing the impact of first-line regimens on HRQoL is essential to evaluate clinical benefit in addition to efficacy and safety in this setting. METHODS: LEAP-002 is a randomized phase III trial of lenvatinib plus pembrolizumab versus lenvatinib plus placebo as first-line treatment for participants with advanced HCC. Patient-reported outcomes (PROs) were prespecified exploratory endpoints assessed in all participants randomly assigned to treatment using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 questionnaire (EORTC QLQ-C30), EORTC QLQ Hepatocellular Carcinoma 18-item module (EORTC QLQ-HCC18), and EuroQol 5-dimension, 5-level questionnaire (EQ-5D-5L) at baseline and throughout the trial. Median time to confirmed deterioration (TTD) in PROs was estimated using the Kaplan-Meier method. Least-squares mean change from baseline to week 27 (latest time point when completion and compliance rates were ≥60% and ≥80%, respectively) in PRO scores was assessed using a constrained longitudinal data analysis model. No formal hypotheses were tested. RESULTS: The PRO population comprised 779 participants (lenvatinib plus pembrolizumab, n = 390; lenvatinib plus placebo, n = 389). Completion rates for all PRO assessments were >94% at baseline and >63% at week 27. Median TTD for EORTC QLQ-C30 global health status/quality-of-life score was 11.5 months [95% confidence interval (CI) 5.6 months-not reached] in the lenvatinib plus pembrolizumab group and 4.3 months (95% CI 3.5-5.5 months) in the lenvatinib plus placebo group (hazard ratio 0.80, 95% CI 0.65-0.98). TTD and least-squares mean change from baseline to week 27 were similar between treatment groups for EORTC QLQ-C30 scales, EORTC QLQ-HCC18 scores, and the EQ-5D-5L visual analog scale. CONCLUSION: Adding pembrolizumab to lenvatinib, which is a current first-line option as a single agent, maintained HRQoL during the first-line treatment of participants with advanced HCC.

KM 提取结果

1 个 Figure · 1 个 KM 面板

进入结果中心
KM Figure1 个面板

Figure 1

Figure 1 Kaplan–Meier estimate of TTD for EORTC QLQ-C30 GHS/QoL score . CI, confidence interval; EORTC, European Organisation for Research and Treatment of Cancer; GHS, global health status; HR, hazard ratio; NR, not reached; QLQ-C30, QoL Questionnaire Core 30; QoL, quality of life; TTD, time to confirmed deterioration.

Kaplan-Meier_estimate_of_TTD_for_EORTC_QLQ-C30_GHS_QoL_score

time to confirmed deterioration

Figure 1 · Panel Kaplan-Meier_estimate_of_TTD_for_EORTC_QLQ-C30_GHS_QoL_score

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel Kaplan-Meier_estimate_of_TTD_for_EORTC_QLQ-C30_GHS_QoL_score 是同一 Figure 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
其他 Figure(2,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 2Figure 2 LSM change from baseline to week 27 in (A) EORTC QLQ-C30 GHS/QoL functional scales, (B) EORTC QLQ-C30 symptom scales, and (C) EORTC QLQ-HCC18 scores. CI, confidence interval; EORTC, European Organisation for Research and Treatment of Cancer; GHS, global health status; HCC, hepatocellular carcinoma; HCC18, hepatocellular carcinoma 18-item; LSM, least squares mean; QoL, quality of life; QLQ-C30, QoL Questionnaire Core 30.
非 KM Figure
Figure 3Figure 3 Overall rates of improvement, stability, and deterioration for EORTC QLQ-C30 scales and EORTC QLQ- HCC18 subscales. EORTC, European Organisation for Research and Treatment of Cancer; GHS, global health status; QLQ-C30, QoL Questionnaire Core 30; QLQ-HCC18, QoL Hepatocellular Carcinoma 18-item; QoL, quality of life.
非 KM Figure